HRP20120652T1 - Organski spojevi - Google Patents

Organski spojevi Download PDF

Info

Publication number
HRP20120652T1
HRP20120652T1 HRP20120652TT HRP20120652T HRP20120652T1 HR P20120652 T1 HRP20120652 T1 HR P20120652T1 HR P20120652T T HRP20120652T T HR P20120652TT HR P20120652 T HRP20120652 T HR P20120652T HR P20120652 T1 HRP20120652 T1 HR P20120652T1
Authority
HR
Croatia
Prior art keywords
staurosporine
benzoyl
crystalline form
solution
compound
Prior art date
Application number
HRP20120652TT
Other languages
English (en)
Croatian (hr)
Inventor
Hoehn Pascale
Koch Bernd
Mutz Michael
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35501294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20120652(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20120652T1 publication Critical patent/HRP20120652T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Extraction Or Liquid Replacement (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HRP20120652TT 2004-11-05 2005-11-03 Organski spojevi HRP20120652T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62534304P 2004-11-05 2004-11-05
US64213105P 2005-01-07 2005-01-07
PCT/EP2005/011789 WO2006048296A1 (en) 2004-11-05 2005-11-03 Organic compounds

Publications (1)

Publication Number Publication Date
HRP20120652T1 true HRP20120652T1 (hr) 2012-09-30

Family

ID=35501294

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20120652TT HRP20120652T1 (hr) 2004-11-05 2005-11-03 Organski spojevi

Country Status (31)

Country Link
US (2) US8198435B2 (enExample)
EP (3) EP1812448B1 (enExample)
JP (4) JP5057986B2 (enExample)
KR (3) KR101333851B1 (enExample)
CN (2) CN102993213A (enExample)
AR (1) AR052322A1 (enExample)
AU (2) AU2005300693B2 (enExample)
BR (1) BRPI0517689A (enExample)
CA (1) CA2584911C (enExample)
CY (1) CY1113059T1 (enExample)
DK (1) DK1812448T3 (enExample)
EC (1) ECSP12007431A (enExample)
ES (1) ES2388142T3 (enExample)
GT (1) GT200500311A (enExample)
HK (1) HK1211587A1 (enExample)
HR (1) HRP20120652T1 (enExample)
IL (3) IL182691A (enExample)
JO (1) JO2897B1 (enExample)
MA (1) MA29033B1 (enExample)
MX (2) MX346525B (enExample)
MY (2) MY147404A (enExample)
NO (2) NO338960B1 (enExample)
NZ (3) NZ599033A (enExample)
PE (3) PE20130377A1 (enExample)
PL (1) PL1812448T3 (enExample)
PT (1) PT1812448E (enExample)
RU (2) RU2394038C2 (enExample)
SI (1) SI1812448T1 (enExample)
TN (1) TNSN07165A1 (enExample)
TW (4) TWI530500B (enExample)
WO (1) WO2006048296A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101462693B1 (ko) * 2006-08-16 2014-11-17 노파르티스 아게 고도 결정질 치료용 화합물의 고체 분산체 제조 방법
EP2327706A1 (en) * 2009-11-30 2011-06-01 Novartis AG Polymorphous forms III and IV of N-benzoyl-staurosporine
KR20160008267A (ko) 2014-07-14 2016-01-22 주식회사 윈스 네트워크 기반 영상감시체계에서의 사용자 행위 분석 시스템
EP3592749A1 (en) * 2017-03-06 2020-01-15 Teva Pharmaceutical Works Ltd. Solid state forms of midostaurin
WO2019215759A1 (en) * 2018-05-09 2019-11-14 Alaparthi Lakshmi Prasad An improved process for preparation of midostaurin
IT201900004729A1 (it) 2019-03-29 2020-09-29 Procos Spa Processo per la preparazione di midostaurina ad elevato grado di purezza
US20220242880A1 (en) * 2019-06-24 2022-08-04 Dr. Reddy?s Laboratories Limited Process for preparation of midostaurin
IT201900014346A1 (it) * 2019-08-08 2021-02-08 Procos Spa Processo per la preparazione di midostaurina amorfa con un basso contenuto di solvente organico residuo
IT202000004291A1 (it) 2020-03-02 2021-09-02 Indena Spa Processo per la purificazione di alcaloidi indolo carbazolici
CN111393454A (zh) * 2020-05-07 2020-07-10 奥锐特药业(天津)有限公司 米哚妥林的新晶型及其制备方法
CN115124551B (zh) * 2021-03-24 2024-04-30 奥锐特药业(天津)有限公司 一种高纯度米哚妥林的制备方法
WO2023205504A1 (en) * 2022-04-22 2023-10-26 Rutgers, The State University Of New Jersey Formulations and methods for treating epidermolysis bullosa simplex and related conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5373501A (en) * 1976-12-11 1978-06-30 Kitasato Inst Novel antibiotics amm2282 and process for preparing same
JPS60185719A (ja) 1984-03-06 1985-09-21 Ajinomoto Co Inc 抗腫瘍剤
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
IL86632A0 (en) * 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5073633A (en) * 1989-03-23 1991-12-17 Bristol-Myers Company BMY-41950 antitumor antibiotic
US5096330A (en) * 1990-06-21 1992-03-17 M-B-W Inc. Pitch control mechanism for a surface finishing machine
JPH05247055A (ja) * 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
JPH05247955A (ja) 1992-03-06 1993-09-24 Taisei Corp 擁壁の施工方法
US5344926A (en) 1992-06-22 1994-09-06 Kyowa Hakko Kogyo Co., Ltd. Process for producing staurosporine derivatives
WO1995032975A1 (en) * 1994-06-01 1995-12-07 Ciba-Geigy Ag Indolocarbazole derivatives for sensitizing multidrug-resistant cells to antitumor agents
RU2191175C2 (ru) * 1995-12-11 2002-10-20 Сефалон, Инкорпорейтед Конденсированные изоиндолоны в качестве ингибиторов протеинкиназы с
BR9917475B1 (pt) * 1999-08-30 2013-07-23 processo para a manufatura de compostos, e, modificação do processo.
CA2439097C (en) 2001-03-26 2010-10-12 Novartis Ag Pharmaceutical compositions
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
WO2004094645A1 (en) * 2003-04-22 2004-11-04 Lonza Ag Process for the recovery of staurosporine from a fermentation broth

Also Published As

Publication number Publication date
RU2467012C2 (ru) 2012-11-20
TW201247680A (en) 2012-12-01
PL1812448T3 (pl) 2012-10-31
GT200500311A (es) 2006-05-22
JP2012149099A (ja) 2012-08-09
IL207702A0 (en) 2010-12-30
JP5701246B2 (ja) 2015-04-15
TNSN07165A1 (en) 2008-11-21
US8198435B2 (en) 2012-06-12
PE20130377A1 (es) 2013-04-03
IL182691A0 (en) 2007-09-20
PE20090433A1 (es) 2009-05-05
US20090137552A1 (en) 2009-05-28
JP2008518995A (ja) 2008-06-05
RU2009137788A (ru) 2011-04-20
TWI530501B (zh) 2016-04-21
MY147404A (en) 2012-11-30
TWI530500B (zh) 2016-04-21
RU2007120695A (ru) 2008-12-10
EP2955186A1 (en) 2015-12-16
WO2006048296A1 (en) 2006-05-11
NO340404B1 (no) 2017-04-18
MY154878A (en) 2015-08-14
MX346525B (es) 2017-03-23
PT1812448E (pt) 2012-08-24
EP2272850A3 (en) 2011-09-21
AU2009245817A1 (en) 2009-12-24
BRPI0517689A (pt) 2008-10-14
US8710216B2 (en) 2014-04-29
JP2015063569A (ja) 2015-04-09
EP1812448B1 (en) 2012-05-23
TWI433852B (zh) 2014-04-11
NO20072290L (no) 2007-05-30
EP1812448A1 (en) 2007-08-01
NO20161152A1 (no) 2007-05-30
US20120322789A1 (en) 2012-12-20
IL217571A (en) 2017-07-31
AR052322A1 (es) 2007-03-14
PE20060947A1 (es) 2006-10-30
JP2017061578A (ja) 2017-03-30
KR20070083979A (ko) 2007-08-24
KR101289998B1 (ko) 2013-07-30
CN102993213A (zh) 2013-03-27
AU2005300693B2 (en) 2010-08-19
NO338960B1 (no) 2016-11-07
HK1211587A1 (en) 2016-05-27
SI1812448T1 (sl) 2012-09-28
TW200628474A (en) 2006-08-16
JO2897B1 (en) 2015-09-15
TW201446773A (zh) 2014-12-16
AU2005300693A1 (en) 2006-05-11
MA29033B1 (fr) 2007-11-01
EP2272850A2 (en) 2011-01-12
NZ599033A (en) 2012-09-28
DK1812448T3 (da) 2012-08-27
NZ588025A (en) 2012-04-27
KR101333851B1 (ko) 2013-11-27
IL182691A (en) 2013-02-28
ECSP12007431A (es) 2012-06-29
TW201247681A (en) 2012-12-01
TWI455941B (zh) 2014-10-11
KR20120101600A (ko) 2012-09-13
CN102627658A (zh) 2012-08-08
AU2009245817B2 (en) 2013-02-21
CA2584911A1 (en) 2006-05-11
KR101265850B1 (ko) 2013-05-20
EP2272850B1 (en) 2017-05-10
JP5057986B2 (ja) 2012-10-24
HK1108881A1 (en) 2008-05-23
CY1113059T1 (el) 2016-04-13
CA2584911C (en) 2017-10-24
KR20120101601A (ko) 2012-09-13
RU2394038C2 (ru) 2010-07-10
NZ554653A (en) 2010-10-29
MX2007005429A (es) 2007-05-18
ES2388142T3 (es) 2012-10-09
IL207702A (en) 2016-09-29

Similar Documents

Publication Publication Date Title
HRP20120652T1 (hr) Organski spojevi
CN102762575A (zh) 多环化合物及其使用方法
CZ303702B6 (cs) Minocyklinové slouceniny
HRP20160246T4 (hr) Dimaleat od aminokrotonilskog spoja i postupak njegove proizvodnje
JP2004502750A (ja) ７、８および９−置換テトラサイクリン化合物
IL228220A (en) Tricyclic inhibitors of the gyrase enzyme
CN105646584A (zh) 替诺福韦艾拉酚胺富马酸盐新晶型及其制备方法和用途
CN101362718A (zh) 4-(4-苯甲酰氨基苯氧基)-2-(甲基氨甲酰基)吡啶衍生物及其制备方法和用途
US20090275585A1 (en) Novel Compounds and Therapeutic Use Thereof for Protein Kinase Inhibition
JP4654187B2 (ja) テクトリゲニンのイソフラボン誘導体、その調製、および有効成分としてこれを含む抗ウィルス剤
EP2168964A4 (en) COUPLED AZAINDOL INDOL DERIVATIVES, MANUFACTURING METHOD AND APPLICATIONS THEREOF
Mathew et al. Novel pyridopyrazine and pyrimidothiazine derivatives as FtsZ inhibitors
WO2004005309A3 (en) Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
WO2011035077A1 (en) Novel compounds and therapeutic use thereof for protein kinase inhibition
CN105051034A (zh) 氮杂环丁烷基氧基苯基吡咯烷化合物
CN118125997A (zh) 紫檀芪丹皮酚查尔酮酰胺类衍生物、其制法及医药用途
WO2019031470A1 (ja) 新規アミド系化合物、並びにそれを用いたＰｉｎ１阻害剤、炎症性疾患の治療剤及び癌の治療剤
CN108299255B (zh) 组蛋白去乙酰化酶8选择性抑制剂及其制备方法和应用
CA2105683C (en) N-¬¬4,5-dihydroxy-and 4,5,8-trihydroxy-9,10-dihydro-9, 10-dioxo-2-anthracene-yl|carbonyl|amino acids useful in the therapy of osteoarticular affections
US20030120073A1 (en) Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases
JPH06505229A (ja) 抗ウイルス薬としてのチアゾロ−［２，３−ａ］−イソインドール誘導体の使用および新規なチアゾロ−［２，３−ａ］−イソインドール誘導体
CN102443005A (zh) 查尔酮的螺杂环类化合物及其用途
ES2544327T3 (es) Sales de amina de un derivado de carboestirilo útiles para el tratamiento de, entre otras, una úlcera gástrica
CN101591230A (zh) 2,4-二羟基查尔酮类衍生物、其制备方法和用途
CN1771240A (zh) 3－苯基呋喃－2－酮衍生物作为环加氧酶的抑制剂